Remedium Lifecare Limited (BSE: 539561), a fast-growing player in pharmaceutical intermediates and specialty chemicals, has received approval from the Bombay Stock Exchange (BSE) for its ₹49.19 crore rights issue. The move is aimed at raising capital from existing shareholders to fund manufacturing expansion, R&D equipment, and meet working capital needs. As per the approved terms, the issue offers 61 equity shares for every 50 fully paid-up shares held on the record date, April 15, 2025, at ₹1 per share. A total of 49.19 crore fully paid-up shares will be issued, with the face value pegged at ₹1 each.
“This approval from the BSE marks a significant milestone in our journey. We remain committed to enhancing shareholder value while scaling up our operations responsibly and sustainably,” said Adarsh Munjal, Whole Time Director, Remedium Lifecare Ltd. The announcement follows Remedium’s recent success in international markets, having bagged a ₹182.7 crore multi-year export deal with a UK-based pharmaceutical distributor in February 2025. The company continues to see strong global demand across key therapeutic areas.
In Kolkata, analysts view the rights issue as a strategic move, anticipating increased investor interest due to the company’s expanding international footprint and low share price. The development is expected to generate buzz among retail investors in the city’s vibrant pharma and small-cap investment community.